ATLANTA (AP) -- Drug development firm AtheroGenics Inc. on Monday said it will receive a $50 million payment from AstraZeneca PLC after regulators cleared a licensing deal between the companies.
AtheroGenics and AstraZeneca have partnered for the worldwide development and commercialization of AtheroGenics' experimental drug for treating atherosclerosis, or clogged arteries.
